iov-3001
·Code: IOV-3001
iov-3001: developed by 1 company · 1 clinical trial tracked.
iov-3001 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect iov-3001 to IOVA; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could iov-3001 → IOVA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Unresectable Melanoma
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Unresectable Melanoma | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel
Primary endpoint: Safety and Tolerability
Interventionalopen42 targetStarted 2025-03Completion 2032-075 sites · Australia, United StatesIovance Biotherapeutics, Inc.
Frequently asked questions
Who is developing iov-3001?
iov-3001 is being developed by IOVANCE BIOTHERAPEUTICS, INC..
How many clinical trials involve iov-3001?
BioSniper tracks 1 clinical trial involving iov-3001.